BG108857A - Glutaminyl based dpiv inhibitors - Google Patents
Glutaminyl based dpiv inhibitorsInfo
- Publication number
- BG108857A BG108857A BG108857A BG10885704A BG108857A BG 108857 A BG108857 A BG 108857A BG 108857 A BG108857 A BG 108857A BG 10885704 A BG10885704 A BG 10885704A BG 108857 A BG108857 A BG 108857A
- Authority
- BG
- Bulgaria
- Prior art keywords
- dpiv inhibitors
- dpiv
- glutaminyl based
- glutaminyl
- based dpiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36090902P | 2002-02-28 | 2002-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108857A true BG108857A (en) | 2005-12-30 |
Family
ID=23419891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108857A BG108857A (en) | 2002-02-28 | 2004-08-25 | Glutaminyl based dpiv inhibitors |
Country Status (27)
Country | Link |
---|---|
US (2) | US6946480B2 (fr) |
EP (1) | EP1480961B1 (fr) |
JP (1) | JP2005527504A (fr) |
KR (1) | KR20040095241A (fr) |
CN (1) | CN1622941A (fr) |
AT (1) | ATE349435T1 (fr) |
AU (1) | AU2002325278A1 (fr) |
BG (1) | BG108857A (fr) |
BR (1) | BR0215622A (fr) |
CA (1) | CA2479812A1 (fr) |
CZ (1) | CZ2004973A3 (fr) |
DE (2) | DE20220238U1 (fr) |
DK (1) | DK1480961T3 (fr) |
EA (1) | EA007434B1 (fr) |
ES (1) | ES2278944T3 (fr) |
HK (1) | HK1067120A1 (fr) |
HU (1) | HUP0600057A2 (fr) |
IL (1) | IL163629A0 (fr) |
MX (1) | MXPA04008278A (fr) |
NO (1) | NO20044038L (fr) |
NZ (1) | NZ534877A (fr) |
PL (1) | PL372316A1 (fr) |
PT (1) | PT1480961E (fr) |
SI (1) | SI1480961T1 (fr) |
SK (1) | SK3622004A3 (fr) |
UA (1) | UA76309C2 (fr) |
ZA (1) | ZA200406813B (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1163594C (zh) * | 1997-09-29 | 2004-08-25 | 尖端医疗有限公司 | 体外造血细胞的刺激 |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US20070293426A1 (en) * | 2001-04-02 | 2007-12-20 | Hans-Ulrich Demuth | Methods for improving islet signaling in diabetes mellitus and for its prevention |
US7196201B2 (en) * | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
JP4887139B2 (ja) | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DE602004010206T2 (de) | 2003-08-13 | 2008-10-09 | Takeda Pharmaceutical Co. Ltd. | Dipeptidyl Peptidase Inhibitoren. |
WO2005020983A2 (fr) * | 2003-09-02 | 2005-03-10 | Prosidion Ltd. | Therapie combinee de regulation glycemique |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2559302C (fr) | 2004-03-15 | 2012-06-19 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyle peptidase |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (fr) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidyl peptidase |
EP1794120B1 (fr) * | 2004-07-23 | 2012-04-11 | Nuada, LLC | Inhibiteurs de peptidase |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
JP2008524331A (ja) * | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
CN1979367B (zh) * | 2005-11-30 | 2013-05-15 | 北京中电华大电子设计有限责任公司 | 采用测试校准提高器件参数精度的方法 |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
DK1971862T3 (da) | 2006-04-11 | 2011-02-14 | Arena Pharm Inc | Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2108960A1 (fr) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY |
CA2756893C (fr) * | 2009-03-30 | 2014-02-11 | Dong-A Pharmaceutical Co., Ltd. | Procede ameliore d'elaboration d'inhibiteur de dipeptidyl peptidase-iv et d'intermediaire |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
CN102453001B (zh) * | 2010-10-22 | 2016-06-01 | 中国医学科学院药物研究所 | 硫代吗啉类化合物及其制备方法和用途 |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE296075C (fr) | ||||
US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
DE2009743A1 (de) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3879541A (en) | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
CH602612A5 (fr) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
DD296075A5 (de) * | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
JPH05508624A (ja) | 1990-04-14 | 1993-12-02 | ニュー イングランド メデカル センター ホスピタルズ インク | ジペプチジル―アミノベプチダーゼ・4型の阻害剤 |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
WO1991017767A1 (fr) | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Procede de traitement de l'inhibition de la dipeptidyle aminopeptidase de type iv |
JPH0819154B2 (ja) | 1991-03-14 | 1996-02-28 | 江崎グリコ株式会社 | ジペプチジルカルボキシペプチダーゼを阻害するペプチド |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
ES2153831T3 (es) | 1991-10-22 | 2001-03-16 | New England Medical Center Inc | Inhibidores de dipeptidil-aminopeptidasa de tipo iv. |
IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
FR2696740B1 (fr) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
WO1995011689A1 (fr) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Utilisation d'inhibiteurs de la dipeptidylaminopeptidase pour bloquer l'entree du vih dans des cellules |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
EP0658568A1 (fr) | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Peptides insulinotropes de type glucagon, compositions les contenant et méthode de préparation |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
CZ389398A3 (cs) | 1996-05-29 | 1999-07-14 | Prototek, Inc. | Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
EP1084129B1 (fr) | 1998-06-05 | 2003-01-22 | Point Therapeutics, Inc. | Composes cycliques de boroproline |
DE19826972A1 (de) | 1998-06-18 | 1999-12-23 | Univ Magdeburg Tech | Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation |
AU4854999A (en) | 1998-07-02 | 2000-01-24 | Invitro Diagnostics, Inc. | Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
AU5480199A (en) | 1998-08-21 | 2000-03-14 | Point Therapeutics, Inc. | Regulation of substrate activity |
WO2000053171A1 (fr) | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv |
WO2001034594A1 (fr) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs |
JP2003523396A (ja) | 2000-02-25 | 2003-08-05 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性の抑制 |
JP2003528135A (ja) | 2000-03-31 | 2003-09-24 | プロバイオドラッグ アーゲー | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 |
US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
DE10025464A1 (de) | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
AU2001288437C1 (en) | 2000-09-09 | 2009-05-21 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
EP1323710B1 (fr) * | 2000-10-06 | 2008-09-10 | Mitsubishi Tanabe Pharma Corporation | Composes azotes a noyau a cinq elements |
-
2002
- 2002-06-27 KR KR10-2004-7013493A patent/KR20040095241A/ko not_active Application Discontinuation
- 2002-06-27 SK SK362-2004A patent/SK3622004A3/sk unknown
- 2002-06-27 UA UA20040907210A patent/UA76309C2/uk unknown
- 2002-06-27 EA EA200401062A patent/EA007434B1/ru not_active IP Right Cessation
- 2002-06-27 JP JP2003571262A patent/JP2005527504A/ja active Pending
- 2002-06-27 IL IL16362902A patent/IL163629A0/xx unknown
- 2002-06-27 EP EP02758280A patent/EP1480961B1/fr not_active Expired - Lifetime
- 2002-06-27 DE DE20220238U patent/DE20220238U1/de not_active Expired - Lifetime
- 2002-06-27 DK DK02758280T patent/DK1480961T3/da active
- 2002-06-27 CA CA002479812A patent/CA2479812A1/fr not_active Abandoned
- 2002-06-27 MX MXPA04008278A patent/MXPA04008278A/es active IP Right Grant
- 2002-06-27 BR BR0215622-9A patent/BR0215622A/pt not_active IP Right Cessation
- 2002-06-27 PT PT02758280T patent/PT1480961E/pt unknown
- 2002-06-27 ES ES02758280T patent/ES2278944T3/es not_active Expired - Lifetime
- 2002-06-27 DE DE60217186T patent/DE60217186T2/de not_active Expired - Fee Related
- 2002-06-27 PL PL02372316A patent/PL372316A1/xx not_active Application Discontinuation
- 2002-06-27 SI SI200230479T patent/SI1480961T1/sl unknown
- 2002-06-27 NZ NZ534877A patent/NZ534877A/en unknown
- 2002-06-27 AU AU2002325278A patent/AU2002325278A1/en not_active Abandoned
- 2002-06-27 CN CNA028284070A patent/CN1622941A/zh active Pending
- 2002-06-27 HU HU0600057A patent/HUP0600057A2/hu unknown
- 2002-06-27 AT AT02758280T patent/ATE349435T1/de not_active IP Right Cessation
- 2002-06-27 CZ CZ2004973A patent/CZ2004973A3/cs unknown
- 2002-09-16 US US10/244,347 patent/US6946480B2/en not_active Expired - Fee Related
-
2004
- 2004-02-13 US US10/779,158 patent/US7060719B2/en not_active Expired - Lifetime
- 2004-08-25 BG BG108857A patent/BG108857A/xx unknown
- 2004-08-26 ZA ZA200406813A patent/ZA200406813B/xx unknown
- 2004-09-24 NO NO20044038A patent/NO20044038L/no not_active Application Discontinuation
- 2004-12-18 HK HK04110052A patent/HK1067120A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US6946480B2 (en) | 2005-09-20 |
EP1480961B1 (fr) | 2006-12-27 |
EA007434B1 (ru) | 2006-10-27 |
JP2005527504A (ja) | 2005-09-15 |
HUP0600057A2 (en) | 2006-05-29 |
CN1622941A (zh) | 2005-06-01 |
AU2002325278A1 (en) | 2003-09-09 |
HK1067120A1 (en) | 2005-04-01 |
NZ534877A (en) | 2006-05-26 |
DE60217186D1 (de) | 2007-02-08 |
CZ2004973A3 (cs) | 2004-12-15 |
PT1480961E (pt) | 2007-02-28 |
SI1480961T1 (sl) | 2007-06-30 |
ZA200406813B (en) | 2006-06-28 |
US20040167191A1 (en) | 2004-08-26 |
DE60217186T2 (de) | 2007-09-27 |
KR20040095241A (ko) | 2004-11-12 |
UA76309C2 (en) | 2006-07-17 |
SK3622004A3 (sk) | 2005-02-04 |
EA200401062A1 (ru) | 2005-02-24 |
MXPA04008278A (es) | 2005-09-20 |
DE20220238U1 (de) | 2003-05-08 |
BR0215622A (pt) | 2004-12-07 |
PL372316A1 (en) | 2005-07-11 |
ATE349435T1 (de) | 2007-01-15 |
CA2479812A1 (fr) | 2003-09-04 |
EP1480961A1 (fr) | 2004-12-01 |
ES2278944T3 (es) | 2007-08-16 |
IL163629A0 (en) | 2005-12-18 |
NO20044038L (no) | 2004-09-28 |
US20030162820A1 (en) | 2003-08-28 |
US7060719B2 (en) | 2006-06-13 |
DK1480961T3 (da) | 2007-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108857A (en) | Glutaminyl based dpiv inhibitors | |
NO20030895L (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
TNSN06022A1 (en) | Use of calcitonin in osteoarthritis | |
HK1188985A1 (zh) | 治療細胞增殖紊亂的化合物和方法 | |
AU2003225295A1 (en) | Substituted pyrroline kinase inhibitors | |
MY141984A (en) | Benzamide inhibitors of the p2x7 receptor | |
IL181473A (en) | Antibodies @ people @ against @@@ beta @@ preparations that include them and use them | |
SG149063A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
MXPA05011643A (es) | 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension. | |
AU2003240517A1 (en) | Substituted pyrrolines as kinase inhibitors | |
MXPA04000622A (es) | Pirazolilcarboxanilidas como funguicidas. | |
MXPA06001134A (es) | Inhibidores de la actividad de la proteina cinasa b. | |
SI1814878T1 (sl) | Spojine spiro-2,4-pirimidindiamina in njihova uporaba | |
WO2003105840A3 (fr) | Inhibiteurs de sphingosine kinase | |
WO2004087073A3 (fr) | Traitement d'etats de demyelinisation | |
WO2004100890A3 (fr) | Procedes lies a la fonction rage g82s et compositions destinees au traitement de troubles inflammatoires | |
MXPA06004308A (es) | Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables. | |
MXPA05005484A (es) | Metodo para mejorar las propiedaes fisico-quimicas de composiciones bituminosas y novedosas composiciones bituminosas con propiedades mejoradas y sus usos. | |
DK1485057T3 (da) | Derivater af azaspiroforbindelser til behandling af smerter | |
MXPA06000507A (es) | Pirazolinas como antagonistas de par-1 para el tratamiento de enfermedades cardiovasculares. | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
EP1608352A4 (fr) | Composes polyamine pour le traitement de maladies induites par le recepteur de la chemokine | |
AU2003243381A8 (en) | Variants of antithrombin iii | |
EP1578368A4 (fr) | Compositions et procedes pour le traitement de la polyarthrite rhumatoide |